TY  - CHAP
AU  - Abelardo Aguilera
AU  - Jesús Loureiro
AU  - Guadalupe Gónzalez-Mateo
AU  - 
Rafael Selgas
AU  - Manuel López-Cabrera
ED  - Abelardo Aguilera Peralta
Y1  - 2013-06-19
PY  - 2013
T1  - The Mesothelial to Mesenchymal Transition a Pathogenic and Therapeutic Key for Peritoneal Membrane Failure
N2  - This book summarizes the advances and new concepts introduced in the last years on peritoneal dialysis (PD) and its complications. PD therapy is a renal replacement peritoneal membrane using a semi-permeable barrier to liquids and solutes. The abdominal cavity with all its components, mesothelial cells, fat tissue, immune system components and others are activated by the PD fluids that although every time are more biocompatible, induce production of molecules with the local and systemic effects. Locally there is a thickening of the peritoneal membrane leading to the failure of this and where the transdifferentiation of mesothelial cells plays a key role. 
Systemically activating abdominal cavity appears to be involved in atherosclerosis, diabetes, hypertension, renal bone disease pathway and others.
BT  - The Latest in Peritoneal Dialysis
SP  - Ch. 2
UR  - https://doi.org/10.5772/56598
DO  - 10.5772/56598
SN  - 
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-05-04
ER  -